Le Lézard
Classified in: Health
Subjects: PER, MAT

Tetra Bio-Pharma Inc. Announces Director Resignation


ORLEANS, ON, June 14, 2019 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes to announce that Mr. Benoit Chotard has tendered his resignation as director of the Corporation, effective immediately, in order to devote time to manage his other professional commitments. Furthermore, Mr. Chotard has advised the Corporation that he will not stand for re-election to the board of directors of the Corporation. The Corporation hereby wishes to withdraw his nomination for election as a director at the upcoming annual general meeting of shareholders scheduled to be held on June 20, 2019 (the "Meeting").

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical multifaced corporation with its primary focus in cannabinoid-based drug discovery and development with a clinical trial program aimed at bringing novel drugs and treatments to patients and their healthcare providers. Tetra Bio-Pharma's subsidiary, Tetra Natural Health, also focuses on the development and commercialization of natural health and self-care products as well as the sale of its hemp energy drinks.

For more information visit: www.tetrabiopharma.com and www.tetranaturalhealth.com 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of CAUMZ and its other drug candidates, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

 

SOURCE Tetra Bio-Pharma Inc


These press releases may also interest you

at 23:00
HERE Mobility, announced today that Medical Travel Companions (MTC), a leading provider of transportation and concierge services for travelers who require assistance, has joined the HERE Mobility Marketplace and made HERE Mobility their leading...

at 22:35
KCI, an Acelity Company, today announced that the Company has been recognized in India as one of the Economic Times' Best Healthcare Brands of 2019. This prestigious award honors brands with robust growth, brand excellence, high customer satisfaction...

at 21:35
Gamida Cell Ltd. , a leading cellular and immune therapeutics company, today announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35...

at 21:00
Motus GI Holdings, Inc., ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced the pricing of its underwritten registered public...

at 21:00
Yisheng Biopharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that it has received Investigational New Drug...

at 20:35
Morphic Holding, Inc. ("Morphic"), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, today announced the pricing of its upsized initial public offering of 6,000,000 shares of its common stock at a price...



News published on 14 june 2019 at 19:23 and distributed by: